Ketamine approved in S'pore for treatment of major depressive disorder

Separately, a clinical trial is underway to test the effectiveness of oral ketamine to alleviate symptoms of treatment-resistant depression. PHOTO: ST FILE
New: Gift this subscriber-only story to your friends and family

SINGAPORE - Ketamine, a controlled substance referred to as a party drug by those who abuse it, is now being used in authorised clinical settings in Singapore to treat patients with major depressive disorder (MDD) who are not responding well to other forms of treatment.

Esketamine has been approved by the authorities and used to treat two patients in Singapore. The modified version of ketamine is being administered via a nasal spray.

Already a subscriber? 

Read the full story and more at $9.90/month

Get exclusive reports and insights with more than 500 subscriber-only articles every month

Unlock these benefits

  • All subscriber-only content on ST app and

  • Easy access any time via ST app on 1 mobile device

  • E-paper with 2-week archive so you won't miss out on content that matters to you

Join ST's WhatsApp Channel and get the latest news and must-reads.